Get the Stockscreener App
2.86
4.35%
-0.13
After Hours:
2.90
0.04
+1.40%
Lexaria Bioscience Corp stock is traded at $2.86, with a volume of 123.31K.
It is down -4.35% in the last 24 hours and down -7.59% over the past month.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
See More
Previous Close:
$2.99
Open:
$3.19
24h Volume:
123.31K
Relative Volume:
1.43
Market Cap:
$6.02M
Revenue:
$368.00K
Net Income/Loss:
$-9.54M
P/E Ratio:
-5.9733
EPS:
-0.4788
Net Cash Flow:
$-9.47M
1W Performance:
-13.86%
1M Performance:
-7.59%
6M Performance:
-80.64%
1Y Performance:
-76.88%
1-Day Range:
$2.81
$3.24
1-Week Range:
$2.43
$3.6235
52-Week Range:
$2.43
$21.60
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
2.86 | 6.02M | 368.00K | -9.54M | -9.47M | -0.4788 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock - Investing News Network
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock - Investing News Network
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - Investing News Network
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - ACCESS Newswire
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - Weatherford Democrat
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - Yahoo! Finance Canada
Lexaria Raises $5.9M in Warrant Exercise Transaction - Minichart
Lexaria Bioscience Raises $5.9 Million Via Warrant Exercise; Issues New Warrants, Engages Wainwright - TradingView
$5.9 million raised as Lexaria issues new rights to buy shares - Stock Titan
Primer: Lexaria Bioscience (LEXX US)Sep 2026 - Smartkarma
Lexaria Raises $5.9 Million Via Warrant Exercise and Issues New Warrants - TipRanks
Lexaria raises $5.9M by exercising warrants at reduced price to fund 2027 operations and R&D. - Pluang
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - investingnews.com
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - corsicanadailysun.com
Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds - TradingView
A potential $5.9 million plus a $2.6 million rebate may fund Lexaria's 2027 research - Stock Titan
LEXX: Introducing DehydraTECH 3.0 - Yahoo Finance
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network
Lexaria to present at H.C. Wainwright Global Investment Conference in September 2026 - Pluang
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference - ncnewsonline.com
A drug-delivery company holds 66 granted patents. Lexaria plans a New York presentation. - Stock Titan
Lexaria Bioscience Corp. (LEXX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Lexaria Bioscience: Advancing Next-Generation Oral Weight-Loss Drugs - The Globe and Mail
LEXX Looks 131.9% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience advances 12% on Australian tax rebate (LEXX:NASDAQ) - Seeking Alpha
Lexaria enters MTA with PegBio to test GLP-1 delivery tech - scanx.trade
LEXX Looks 129.0% Overvalued on GF Value™ - GuruFocus
Lexaria advances GLP-1 partnerships at BIO 2026 - scanx.trade
Lexaria Bioscience Receives Australian R&D Tax Incentive Credit - TipRanks
LEXX Looks 117.5% Overvalued on GF Value™ - GuruFocus
Lexaria receives $2.6 million Australian R&D tax rebate By Investing.com - Investing.com South Africa
Lexaria receives $2.6 million Australian R&D tax rebate By Investing.com - Investing.com Nigeria
Lexaria receives $2.6 million Australian R&D tax rebate By Investing.com - Investing.com India
Lexaria receives $2.6 million Australian R&D tax rebate By Investing.com - Investing.com Canada
Lexaria Bioscience receives AUD$3.67m Australian tax rebate - scanx.trade
Lexaria receives $2.6 million Australian R&D tax rebate - Investing.com
Lexaria nets $2.6M Australian tax rebate to fun... - Pluang
Lexaria Bioscience receives AUD 3.67M Australian R&D tax credit to fund clinical RD - TradingView
Lexaria receives $2.6 million Australian R&D tax rebate By Investing.com - Investing.com UK
Lexaria Receives USD$2.6 Million Tax Rebate Payment - ncnewsonline.com
Lexaria Receives USD$2.6 Million Tax Rebate Payment - Yahoo Finance
Lexaria DehydraTECH 3.0 Boosts GLP-1 Drug Absorption in 2026 Study - TipRanks
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2 - Yahoo Finance
Lexaria Bioscience Corp (NASDAQ: LEXX) Share Price, LEXX Stock News, LEXX Share Price & Updates - Kalkine
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed By Investing.com - Investing.com India
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed By Investing.com - Investing.com South Africa
Form 8K LEXARIA BIOSCIENCE CORP. For: 17 August By Investing.com - Investing.com Nigeria
Form 8K LEXARIA BIOSCIENCE CORP. For: 17 August By Investing.com - Investing.com South Africa
Lexaria Bioscience Regains Nasdaq Compliance, Stabilizing Listing - TipRanks
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed - Investing.com
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):